Potencial de plantas medicinais como terapia complementar a COVID 19
DOI:
https://doi.org/10.34119/bjhrv8n4-213Keywords:
COVID-19, plantas medicinais, antiviraisAbstract
A COVID-19 é uma doença causada pelo vírus SARS-CoV-2 que teve alcance pandêmico em 2020. Houve rápida disseminação, e com isso alto índice de mortalidade, dificuldades de tratamento e conduções terapêuticas. Até os dias atuais o tratamento da COVID-19 ainda é uma demanda, e nesse contexto entram as plantas medicinais o qual atualmente são grande alvo de estudos, afim de entender as propriedades antioxidantes, antinflamatórios, antivirais e ação imunomoduladora de seus compostos. Visando revisar os estudos atuais da ação de plantas medicinais como terapia complementar no tratamento da COVID-19 foi realizado uma pesquisa integrativa na base de dados PubMed utilizando alguns termos na língua inglesa como: “COVID-19”, “SARS-CoV”, “Coronavírus” e “Medicinal Plants”, buscando estudos clínicos e randomizados, e com isso reuniu-se 15 estudos e 51 extratos. Podemos destacar a ação extratos Polygonum cuspidatum, Forsythia suspensa, Isatis indigotica, Bupleurum chinense, Patrinia scabiosifolia, Verbena officinalis, Phragmites communis, Glycyrrhiza uralensis, Swasari ras, Giloy ghanvati, Ashwagandha, Tulsi ghanvati e Anu taila os quais demonstraram ação imunomoduladora, redução de sintomas e redução da replicação viral, que em conjunto com o tratamento precoce contribuíram para melhora mais rápida dos pacientes do grupo tratamento quando comparados com o grupo placebo. Demais extratos também demonstraram redução na sintomatologia dos pacientes. Com isso concluímos que os extratos são potenciais tratamentos promissores para pacientes com COVID-19 leve a moderado a ser utilizados como terapia complementar.
References
BORUJERDI, R. et al. Effects of Iranian Polyherbal Syrup (Zufa syrup) on oxygen saturation and clinical symptoms in suspected patients with COVID-19: a triple-blinded, randomized, placebo-controlled trial. Medical Gas Research, v. 12, n. 2, p. 44–50, 1 abr. 2022.
BOTOSSO, V. F. et al. Anti-SARS-CoV-2 equine F (Ab′)2 immunoglobulin as a possible therapy for COVID-19. Scientific Reports, v. 12, n. 1, p. 3890, 10 mar. 2022.
CHAMS, N. et al. COVID-19: A Multidisciplinary Review. Frontiers in Public Health, v. 8, 29 jul. 2020.
DEVPURA, G. et al. Randomized placebo-controlled pilot clinical trial on the efficacy of ayurvedic treatment regime on COVID-19 positive patients. Phytomedicine, v. 84, p. 153494, 1 abr. 2021.
EBRAHIMI, M. et al. Evaluating the efficacy of extracted squalene from seed oil in the form of microemulsion for the treatment of COVID‐19: A clinical study. Journal of Medical Virology, v. 94, n. 1, p. 119–130, 26 ago. 2021.
FANG, E. et al. Advances in COVID-19 mRNA vaccine development. Signal Transduction and Targeted Therapy, v. 7, n. 94, p. 94, 23 mar. 2022.
FOROUZANFAR, F. et al. The Effect of Pomegranate Juice and Sumac Consumption in the Treatment of Outpatients with COVID-19. Mediators of Inflammation, v. 2022, p. 6850342, 2022.
HAQ, I. Safety of medicinal plants. Pakistan Journal of Medical Research, v. 43, n. 4, 2004.
HASANPOUR, M. et al. Efficacy of Covexir® (Ferula foetida oleo‐gum) treatment in symptomatic improvement of patients with mild to moderate COVID‐19: A randomized, double‐blind, placebo‐controlled trial. Phytotherapy Research, 27 jul. 2022.
HORBY, P. et al.. Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. New England Journal of Medicine, v. 383, n. 21, p. 2030–2040, 8 out. 2020.
KARIMI, M. et al. Efficacy of Persian medicine herbal formulations (capsules and decoction) compared to standard care in patients with COVID‐19, a multicenter open‐labeled, randomized, controlled clinical trial. Phytotherapy Research, v. 35, n. 11, p. 6295–6309, 4 out. 2021.
KOSARI, M. et al. The effect of propolis plus Hyoscyamus niger L. methanolic extract on clinical symptoms in patients with acute respiratory syndrome suspected to COVID-19: A clinical trial. Phytotherapy Research, v. 35, n. 7, p. 4000–4006, 1 jul. 2021.
KOSHAK, A. E. et al. Nigella sativa for the treatment of COVID-19: An open-label randomized controlled clinical trial. Complementary Therapies in Medicine, v. 61, p. 102769, set. 2021.
MEHRABAN, M. S. A. et al. Efficacy and safety of add-on Viola odorata L. in the treatment of COVID-19: A randomized double-blind controlled trial. Journal of Ethnopharmacology, v. 304, p. 116058, mar. 2023.
NOGUEIRA, J. V. D. CONHECENDO A ORIGEM DO SARS-COV-2 (COVID 19). Revista Saúde e Meio Ambiente, v. 11, n. 2, p. 115–124, 9 out. 2020.
Painel Coronavírus Brasil - https://covid.saude.gov.br/;
RANGNEKAR, H. et al. Safety and efficacy of herbal extracts to restore respiratory health and improve innate immunity in COVID-19 positive patients with mild to moderate severity: A structured summary of a study protocol for a randomised controlled trial. Trials, v. 21, n. 1, 23 nov. 2020.
SINGH, H. et al. AYUSH-64 as an adjunct to standard care in mild to moderate COVID-19: An open-label randomized controlled trial in Chandigarh, India. Complementary Therapies in Medicine, v. 66, p. 102814–4, 1 jun. 2022.
SINGHAL, T. A review of coronavirus disease-2019 (COVID-19). The Indian Journal of Pediatrics, v. 87, n. 4, p. 281–286, 13 mar. 2020.
VARNASSERI, M. et al. The effects of add-on therapy of Phyllanthus Emblica (Amla) on laboratory confirmed COVID-19 Cases: A randomized, double-blind, controlled trial. Complementary Therapies in Medicine, v. 65, p. 102808, 1 maio 2022.
WON, E. S. et al. Efficacy of Liriope platyphylla extract on improving respiratory function: A CONSORT-randomized, double-blind, placebo-controlled pilot trial. Medicine, v. 101, n. 35, p. e30073, 2 set. 2022.
World Health Organization (WHO) - https://covid19.who.int/;
XIA, L. et al. Shufeng Jiedu, a promising herbal therapy for moderate COVID-19:Antiviral and anti-inflammatory properties, pathways of bioactive compounds, and a clinical real-world pragmatic study. Phytomedicine, p. 153390, out. 2020.
ZAMPARELLI, S. S. et al. A Phase II Study on the Effect of Taurisolo® Administered via AEROsol in Hospitalized Patients with Mild to Moderate COVID-19 Pneumonia: The TAEROVID-19 Study. Cells, v. 11, n. 9, p. 1499, 29 abr. 2022.
